C
아이엠비디엑스
461030KOSDAQ자연과학 및 공학 연구개발업53.0 / 100
Reference Date: 2026-07-24
Financial Score26.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 11.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
IMBIX is a global healthcare company leading the way in precision cancer diagnosis and early detection using liquid biopsy and next-generation sequencing (NGS) technologies. Its core business areas include precision diagnosis of advanced cancers, early detection of post-surgical recurrence, and early cancer screening, supported by products like AlphaLiquide®100 and HRR.
Number of Employees
65people
Average Salary
58.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 43.644.0Point
PBR
1.77Industry Average 2.525.5Point
Lower than industry avg (good)
ROE
-27.54Industry Average -32.093.5Point
Below industry avg
Debt Ratio
1.67Industry Average 7.318.0Point
Half of industry avg (excellent)
Trend 2024~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲56.4% (1-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲18.4% (1-year basis)
ROE Trend
0.0 / 4
Avg ROE -37.3% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (1%, downtrend)
Current 3,115Won52-week high 12,08052-week low 2,965
1-month return1.0Point
1m -11.63% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-09
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-07
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-30
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-30
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-29